Extracted from this filing and checked against the source text.
Debt Financings
SEC 8-K Item 2.03/2.04
confidence 0.9
Revolution Medicines, Inc. incurred convertible notes of $500,000,000 aggregate principal amount with U.S. Bank Trust Company, National Association at 0.50% per annum maturing May 1, 2033.
- Instrument
- convertible notes
- Principal
- $500,000,000 aggregate principal amount
- Counterparty
- U.S. Bank Trust Company, National Association
- Rate
- 0.50% per annum
- Maturity
- May 1, 2033
- Event
- incurrence
Exact text from the filing
On April 17, 2026, Revolution Medicines, Inc. (the “Company”) issued $500,000,000 aggregate principal amount of its 0.50% Convertible Senior Notes due 2033 (the “Notes”).
View on SEC.gov
Material Agreements
SEC 8-K Item 1.01/1.02
confidence 0.99
Revolution Medicines, Inc. entered into Indenture with U.S. Bank Trust Company, National Association valued at $500,000,000 aggregate principal amount (effective 2026-04-17).
- Action
- entry
- Agreement
- notes offering
- Counterparty
- U.S. Bank Trust Company, National Association
- Value
- $500,000,000 aggregate principal amount
- Effective
- 2026-04-17
Exact text from the filing
On April 17, 2026, Revolution Medicines, Inc. (the “Company”) issued $500,000,000 aggregate principal amount of its 0.50% Convertible Senior Notes due 2033 (the “Notes”). The Notes were issued pursuant to, and are governed by, an indenture (the “Base Indenture”), dated as of April 17, 2026, between the Company and U.S. Bank Trust Company, National Association, as trustee (the “Trustee”), as supplemented by a First Supplemental Indenture (the “Supplemental Indenture,” and the Base Indenture, as supplemented by the Supplemental Indenture, the “Indenture”), dated as of April 17, 2026, between the Company and the Trustee.
View on SEC.gov